CALL FOR POSTER ABSTRACTS

Due by Wednesday, August 12, 2015

CALL FOR POSTER ABSTRACTS

DIA/FDA Oligonucleotide-Based Therapeutics Conference 2015
September 9-11 | Washington, DC

POSTER ABSTRACT SUBMISSION DETAILS and GUIDELINES

SUBMISSION DEADLINE: WEDNESDAY, AUGUST 12

POSTER ABSTRACT SUBMISSION OVERVIEW AND TOPICS

Please submit your poster abstracts based on the primary interest area topics, listed within the right column, in support of the Nonclinical, CMC, and Clinical Session Tracks.

NONCLINICAL TRACK

The nonclinical sessions are designed to provide updates and discussion on recent advancements in nonclinical development of oligonucleotide therapeutics. Session topics within this track include: GalNAc conjugates, miRNA therapeutics, mRNA therapeutics, injection-site reactions (a joint session with the Clinical Track), and thrombocytopenia (a joint session with the Clinical Track).

CLINICAL DEVELOPMENT TRACK

These sessions will provide updates on the recent progress made with oligonucleotides in the clinic. Programs in various stages of development will highlight the challenges faced, lessons learned, and offer potential solutions and innovative ideas for clinical development of oligonucleotide therapeutics. Session topics within this track include: neuromuscular, cardio/metabolic, antiviral, injection site reactions (a joint topic with the Nonclinical Track), oncology, and thrombocytopenia (a joint topic with the Nonclinical Track).

CHEMISTRY, MANUFACTURING, AND CONTROLS (CMC) TRACK

The CMC track will cover a wide range of current oligonucleotide science and feature expert speakers from industry and regulatory agencies. Session topics within this track include: opportunities and challenges in Asia, emerging trends, analytical method validation, conjugates, and impurities (a joint topic with the Nonclinical Track).

POSTER ABSTRACT SUBMISSION DEADLINE: August 12

NOTIFICATION: Week of August 17

CONFERENCE DATE: September 9-11

LOCATION: Grand Hyatt Washington
1000 H Street NW
Washington, DC 20001

POSTER SESSION: September 9 from 4:30-5:30PM

POSTER SET UP: September 9 (time to be determined)

Please submit all abstracts online at: DIAglobal.org/Abstract

PRIMARY INTEREST AREA TOPICS FOR POSTER SUBMISSION:

- Assay Development and Optimization
- Clinical Pharmacology
- Clinical Safety
- Clinical Updates
- Formulations
- Hot Topics
- Impurities
- Manufacturing
- Metabolic Disease
- Miscellaneous
- Neuromuscular Conditions
- Nonclinical Efficacy Models
- Nonclinical Toxicology
- Novel Mechanisms for Intervention
- Novel Oligonucleotide Therapeutics
- Oncology
- Oligonucleotide ADME
- Oligonucleotide Conjugation and Tissue Targeting
- Oligonucleotide Regulatory Guidance
- Oligonucleotide Therapeutics for Rare Diseases
- Regulatory
- Target Identification Screening Methods (Discovery)
- Targeting and Delivery
- Translational Experience
- Trends in Oligonucleotide Toxicology

Submit Your Abstract at DIAglobal.org/Abstract
SUBMITTED POSTER ABSTRACTS MUST INCLUDE THE FOLLOWING SECTIONS:
The following information will be requested at the time of submission.

To streamline your submission process and avoid possible delays, DIA strongly encourages you to submit your poster abstract as early as possible. **Do not wait until the last day.**

Prepare your abstract in advance of accessing the DIA website. Abstract information should be copied and pasted from a prepared document as plain text. **All of the below fields are required.**

**Author Information** - The following information will need to be completed. **NOTE:** If you are submitting on behalf of the author, you are considered the SUBMITTER and will need to complete the required information for yourself AND also for the AUTHOR. Submitters will be the contact regarding the status of the abstract. If you are submitting your own abstract, you are considered the AUTHOR and will be the direct contact for this abstract.

Prefix:
First Name:
Middle Name:
Last Name:
Name Suffix:
Degrees:
Job Title:
Company:
Country:
Address Line 1:
City:
State/Province:
Zip/Postal Code:
Phone:
Email:

Abstract Title (Maximum 125 characters including spaces) - Titles should briefly describe the focus of the abstract as well as accurately reflect the content of the abstract.

Primary Interest Area - Select the interest area that best relates to your abstract.

Keyword (Maximum 100 characters including spaces) - One or more key words are to be provided to highlight your abstract. Examples of key words: Personalized Medicine, Health Technology Assessment, Clinical Trial Agreements.

Objective (Maximum 300 characters including spaces) - Please provide a one sentence statement of the objective of the abstract.

Method (Maximum 300 characters including spaces) - When, where, and how was the study done? What materials were used or who was included in the study?

Results (Maximum 2000 characters including spaces) - What quantitative data was collected; what answer was found to the research question; what did the study find? Was the tested hypothesis true?

Conclusion (Maximum 2000 characters including spaces) - State what can be concluded from the study and its implications.

If you have co-authors, please list them in either the results or conclusion section. At this time, there is no specific field in the system to collect these names.

Abstracts will be reviewed, and authors will be notified of results the week of August 17, 2015.